deltatrials
Completed PHASE1 INTERVENTIONAL 2-arm NCT00406796

Lucentis for Central Retinal Vein Occlusion (CRVO)

FVF3565s Intravitreal Ranibizumab (rhuFab V2) in the Treatment of Macular Edema Associated With Perfused Central (CRVO) Retinal Venous Occlusive Disease

Sponsor: California Retina Consultants

Conditions Central Retinal Vein Occlusion
Interventions Ranibizumab
Updated 5 times since 2017 Last updated: Dec 10, 2013 Started: Jan 31, 2006 Primary completion: Sep 30, 2008 Completion: Oct 31, 2010
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00406796, this PHASE1 trial focuses on Central Retinal Vein Occlusion and remains completed. Sponsored by California Retina Consultants, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • California Retina Consultants
  • Genentech, Inc.
Data source: California Retina Consultants

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations